Douglas Ball

Research output

Research output per year 1992 1993 1994 1996 1997 2000 2001 2003 2004 2005 2006 2007 2009 2010 2011 2013 2015 2022

• 62 Article
• 12 Review article
• 4 Comment/debate
• 3 Chapter
• 2 More
  • 1 Editorial
  • 1 Letter

Research output per year

Research output per year

Search results

• 2022

  Lenvatinib-related renal microangiopathy: a case series

  Delsante, M., Monroy-Trujillo, J. M., Carter-Monroe, N., Ball, D. W. & Rosenberg, A. Z., Feb 2022, In: Virchows Archiv. 480, 2, p. 467-473 7 p.

  Research output: Contribution to journal › Article › peer-review

  • lenvatinib 100%
  • Thrombotic Microangiopathies 61%
  • Kidney 32%
  • Thyroid Neoplasms 30%
  • Glomerular Basement Membrane 19%

• Thyroid Carcinoma, Version 2.2022 NCCN CLINICAL PRACTICE GUIDELINES IN ONCOLOGY

  Haddad, R. I., Bischoff, L., Ball, D., Bernet, V., Blomain, E., Busaidy, N. L., Campbell, M., Dickson, P., Duh, Q. Y., Ehya, H., Goldner, W. S., Guo, T., Haymart, M., Holt, S., Hunt, J. P., Iagaru, A., Kandeel, F., Lamonica, D. M., Mandel, S., Markovina, S., & 16 othersMcIver, B., Raeburn, C. D., Rezaee, R., Ridge, J. A., Roth, M. Y., Scheri, R. P., Shah, J. P., Sipos, J. A., Sippel, R., Sturgeon, C., Wang, T. N., Wirth, L. J., Wong, R. J., Yeh, M., Cassara, C. J. & Darlow, S., Aug 2022, In: JNCCN Journal of the National Comprehensive Cancer Network. 20, 8, p. 925-951 27 p.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • Thyroid Neoplasms 100%
  • Practice Guidelines 92%
  • Anaplastic Thyroid Carcinoma 56%
  • Iodine-131 55%
  • Medullary Thyroid cancer 49%
• 2020

  Management of postoperative hypercalcitoninemia in medullary thyroid carcinoma

  Ball, D. W., Dec 15 2020, Thyroid Cancer: A Case-Based Approach. Springer International Publishing, p. 311-318 8 p.

  Research output: Chapter in Book/Report/Conference proceeding › Chapter

  • Medullary Thyroid cancer 100%
  • Calcitonin 90%
  • cabozantinib 31%
  • Familial medullary thyroid carcinoma 31%
  • N-(4-bromo-2-fluorophenyl)-6-methoxy-7-((1-methylpiperidin-4-yl)methoxy)quinazolin-4-amine 31%
• 2019

  A phase i trial of the VEGF receptor tyrosine kinase inhibitor pazopanib in combination with the MEK inhibitor trametinib in advanced solid tumors and differentiated thyroid cancers

  Kurzrock, R., Ball, D. W., Zahurak, M. L., Nelkin, B. D., Subbiah, V., Ahmed, S., O'Connor, A., Karunsena, E., Parkinson, R. M., Bishop, J. A., Ha, Y., Sharma, R., Gocke, C. D., Zinner, R., Rudek, M. A., Sherman, S. I. & Azad, N. S., Sep 15 2019, In: Clinical Cancer Research. 25, 18, p. 5475-5484 10 p.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • trametinib 100%
  • pazopanib 95%
  • Vascular Endothelial Growth Factor Receptor 76%
  • Mitogen-Activated Protein Kinase Kinases 69%
  • Thyroid Neoplasms 64%
  6 Scopus citations

• Genomic Profiling of Parathyroid Carcinoma Reveals Genomic Alterations Suggesting Benefit from Therapy

  Kang, H., Pettinga, D., Schubert, A. D., Ladenson, P. W., Ball, D. W., Chung, J. H., Schrock, A. B., Madison, R., Frampton, G. M., Stephens, P. J., Ross, J. S., Miller, V. A. & Ali, S. M., Jun 2019, In: Oncologist. 24, 6, p. 791-797 7 p.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • Parathyroid Neoplasms 100%
  • Tumor Burden 28%
  • Mutation 27%
  • Neoplasms 25%
  • Hypercalcemia 21%
  8 Scopus citations
• 2017

  Overall survival analysis of EXAM, a phase III trial of cabozantinib in patients with radiographically progressive medullary thyroid carcinoma

  Schlumberger, M., Elisei, R., Müller, S., Schöffski, P., Brose, M., Shah, M., Licitra, L., Krajewska, J., Kreissl, M. C., Niederle, B., Cohen, E. E. W., Wirth, L., Ali, H., Clary, D. O., Yaron, Y., Mangeshkar, M., Ball, D., Nelkin, B. & Sherman, S., Nov 2017, In: Annals of Oncology. 28, 11, p. 2813-2819 7 p.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • cabozantinib 100%
  • Medullary Thyroid cancer 78%
  • Survival Analysis 60%
  • Placebos 24%
  • Survival 14%
  64 Scopus citations
• 2016

  A phase II trial of the multitargeted tyrosine kinase inhibitor lenvatinib (E7080) in advanced medullary thyroid cancer

  Schlumberger, M., Jarzab, B., Cabanillas, M. E., Robinson, B., Pacini, F., Ball, D. W., McCaffrey, J., Newbold, K., Allison, R., Martins, R. G., Licitra, L. F., Shah, M. H., Bodenner, D., Elisei, R., Burmeister, L., Funahashi, Y., Ren, M., O'Brien, J. P. & Sherman, S. I., Jan 1 2016, In: Clinical Cancer Research. 22, 1, p. 44-53 10 p.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • lenvatinib 100%
  • Medullary Thyroid cancer 76%
  • Protein-Tyrosine Kinases 55%
  • Response Evaluation Criteria in Solid Tumors 38%
  • Confidence Intervals 36%
  123 Scopus citations
• 2015

  Anaplastic thyroid carcinoma, version 2.2015

  Haddad, R. I., Lydiatt, W. M., Ball, D. W., Busaidy, N. L., Byrd, D., Callender, G., Dickson, P., Duh, Q. Y., Ehya, H., Haymart, M., Hoh, C., Hunt, J. P., Iagaru, A., Kandeel, F., Kopp, P., Lamonica, D. M., McCaffrey, J. C., Moley, J. F., Parks, L., Raeburn, C. D., & 10 othersRidge, J. A., Ringel, M. D., Scheri, R. P., Shah, J. P., Smallridge, R. C., Sturgeon, C., Wang, T. N., Wirth, L. J., Hoffmann, K. G. & Hughes, M., Sep 1 2015, In: JNCCN Journal of the National Comprehensive Cancer Network. 13, 9, p. 1140-1150 11 p.

  Research output: Contribution to journal › Review article › peer-review

  Open Access

  • Anaplastic Thyroid Carcinoma 100%
  • Docetaxel 78%
  • Thyroid Neoplasms 71%
  • Practice Guidelines 65%
  • Doxorubicin 65%
  57 Scopus citations

• A phase 2 trial of lenvatinib (E7080) in advanced, progressive, radioiodine-refractory, differentiated t

  Cabanillas, M. E., Schlumberger, M., Jarzab, B., Martins, R. G., Pacini, F., Robinson, B., McCaffrey, J. C., Shah, M. H., Bodenner, D. L., Topliss, D., Andresen, C., O'Brien, J. P., Ren, M., Funahashi, Y., Allison, R., Elisei, R., Newbold, K., Licitra, L. F., Sherman, S. I. & Ball, D. W., Aug 1 2015, In: Cancer. 121, 16, p. 2749-2756 8 p.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • lenvatinib 100%
  • Progression-Free Survival 36%
  • Thyroid Neoplasms 20%
  • Confidence Intervals 18%
  • Vascular Endothelial Growth Factor A 17%
  105 Scopus citations

• A phase I trial of vertical inhibition of IGF signalling using cixutumumab, an anti-IGF-1R antibody, and selumetinib, an MEK 1/2 inhibitor, in advanced solid tumours

  Wilky, B. A., Rudek, M. A., Ahmed, S., Laheru, D. A., Cosgrove, D., Donehower, R. C., Nelkin, B., Ball, D., Doyle, L. A., Chen, H., Ye, X., Bigley, G., Womack, C. & Azad, N. S., Jan 6 2015, In: British journal of cancer. 112, 1, p. 24-31 8 p.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • anti-IGF-1R antibody A12 100%
  • AZD 6244 84%
  • Mitogen-Activated Protein Kinase Kinases 55%
  • Antibodies 28%
  • Maximum Tolerated Dose 17%
  32 Scopus citations

• Intraoperative hypertensive crisis due to a catecholamine-secreting esthesioneuroblastoma

  Salmasi, V., Schiavi, A., Binder, Z. A., Ruzevick, J., Orr, B. A., Burger, P. C., Ball, D. W., Blitz, A. M., Koch, W. M., Ishii, M. & Gallia, G. L., Jun 1 2015, In: Head and Neck. 37, 6, p. E74-E80

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • Catecholamines 61%
  • Hypertension 14%
  • Tyrosine 3-Monooxygenase 12%
  • Skull Base 12%
  • Adrenergic Receptors 10%
  4 Scopus citations

• Trametinib with and without pazopanib has potent preclinical activity in thyroid cancer

  Ball, D. W., Jin, N., Xue, P., Bhan, S., Ahmed, S. R., Rosen, D. M., Schayowit Z, A., Clark, D. P. & Nelkin, B. D., Nov 1 2015, In: Oncology reports. 34, 5, p. 2319-2324 6 p.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • trametinib 100%
  • pazopanib 95%
  • Thyroid Neoplasms 64%
  • MAP Kinase Signaling System 20%
  • Clinical Trials 11%
  13 Scopus citations
• 2014

  Thyroid carcinoma, version 2.2014: Featured updates to the NCCN guidelines

  Tuttle, R. M., Haddad, R. I., Ball, D. W., Byrd, D., Dickson, P., Duh, Q. Y., Ehya, H., Haymart, M., Hoh, C., Hunt, J. P., Iagaru, A., Kandeel, F., Kopp, P., Lamonica, D. M., Lydiatt, W. M., McCaffrey, J., Moley, J. F., Parks, L., Raeburn, C. D., Ridge, J. A., & 10 othersRingel, M. D., Scheri, R. P., Shah, J. P., Sherman, S. I., Sturgeon, C., Waguespack, S. G., Wang, T. N., Wirth, L. J., Hoffmann, K. G. & Hughes, M., Dec 1 2014, In: JNCCN Journal of the National Comprehensive Cancer Network. 12, 12, p. 1671-1680 10 p.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • Thyroid Neoplasms 100%
  • Guidelines 63%
  • Phosphotransferases 45%
  • cabozantinib 31%
  • N-(4-bromo-2-fluorophenyl)-6-methoxy-7-((1-methylpiperidin-4-yl)methoxy)quinazolin-4-amine 31%
  104 Scopus citations
• 2013

  Cabozantinib in progressive medullary thyroid cancer

  Elisei, R., Schlumberger, M. J., Müller, S. P., Schöffski, P., Brose, M. S., Shah, M. H., Licitra, L., Jarzab, B., Medvedev, V., Kreissl, M. C., Niederle, B., Cohen, E. E. W., Wirth, L. J., Ali, H., Hessel, C., Yaron, Y., Ball, D., Nelkin, B. & Sherman, S. I., Oct 10 2013, In: Journal of Clinical Oncology. 31, 29, p. 3639-3646 8 p.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • cabozantinib 100%
  • Medullary Thyroid cancer 78%
  • Placebos 23%
  • Progression-Free Survival 20%
  • Transfection 14%
  613 Scopus citations

• Exomic sequencing of medullary thyroid cancer reveals dominant and mutually exclusive oncogenic mutations in RET and RAS

  Agrawal, N., Jiao, Y., Sausen, M., Leary, R., Bettegowda, C., Roberts, N. J., Bhan, S., Ho, A. S., Khan, Z., Bishop, J., Westra, W. H., Wood, L. D., Hruban, R. H., Tufano, R. P., Robinson, B., Dralle, H., Toledo, S. P. A., Toledo, R. A., Morris, L. G. T., Ghossein, R. A., & 8 othersFagin, J. A., Chan, T. A., Velculescu, V. E., Vogelstein, B., Kinzler, K. W., Papadopoulos, N., Nelkin, B. D. & Ball, D. W., Feb 2013, In: Journal of Clinical Endocrinology and Metabolism. 98, 2, p. E364-E369

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • Oncogenic 100%
  • Medullary Thyroid cancer 90%
  • Thyroid 89%
  • Mutation 60%
  • Exome 15%
  139 Scopus citations

• Misidentification of putative medullary thyroid cancer cell lines RO-H85-1 and RO-D81-1

  Dadon, T., Ball, D. & Nelkin, B. D., Mar 2013, In: Journal of Clinical Endocrinology and Metabolism. 98, 3, p. 954-955 2 p.

  Research output: Contribution to journal › Comment/debate › peer-review

  Open Access
  5 Scopus citations

• Serendipity in the diagnosis of pheochromocytoma

  Oshmyansky, A. R., Mahammedi, A., Dackiw, A., Ball, D. W., Schulick, R. D., Zeiger, M. A. & Siegelman, S. S., 2013, In: Journal of computer assisted tomography. 37, 5, p. 820-823 4 p.

  Research output: Contribution to journal › Article › peer-review

  • Pheochromocytoma 100%
  • Renal Artery Obstruction 10%
  • Incidental Findings 9%
  • Liver Function Tests 9%
  • Hematuria 8%
  11 Scopus citations
• 2012

  Insights into the achaete-scute homolog-1 gene (hASH1) in normal and neoplastic human lung

  Miki, M., Ball, D. W. & Linnoila, R. I., Jan 2012, In: Lung Cancer. 75, 1, p. 58-65 8 p.

  Research output: Contribution to journal › Article › peer-review

  • Lung 100%
  • Genes 75%
  • Neuroendocrine Cells 59%
  • Neuroendocrine Carcinoma 40%
  • Synaptophysin 38%
  30 Scopus citations
• 2011

  Activity of XL184 (cabozantinib), an oral tyrosine kinase inhibitor, in patients with medullary thyroid cancer

  Kurzrock, R., Sherman, S. I., Ball, D. W., Forastiere, A. A., Cohen, R. B., Mehra, R., Pfister, D. G., Cohen, E. E. W., Janisch, L., Nauling, F., Hong, D. S., Ng, C. S., Ye, L., Gagel, R. F., Frye, J., Müller, T., Ratain, M. J. & Salgia, R., Jul 1 2011, In: Journal of Clinical Oncology. 29, 19, p. 2660-2666 7 p.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • cabozantinib 100%
  • Medullary Thyroid cancer 78%
  • Protein-Tyrosine Kinases 56%
  • Vascular Endothelial Growth Factor Receptor-2 15%
  • Mucositis 14%
  411 Scopus citations

• Incidentally discovered medullary thyroid cancer: Diagnostic strategies and treatment

  Ahmed, S. R. & Ball, D. W., May 2011, In: Journal of Clinical Endocrinology and Metabolism. 96, 5, p. 1237-1245 9 p.

  Research output: Contribution to journal › Review article › peer-review

  Open Access

  • Medullary Thyroid cancer 100%
  • Thyroid 98%
  • Calcitonin 85%
  • Thyroidectomy 49%
  • Pentagastrin 34%
  56 Scopus citations

• Management of medullary thyroid cancer

  Ball, D. W., Mar 2011, In: Minerva endocrinologica. 36, 1, p. 87-98 12 p.

  Research output: Contribution to journal › Review article › peer-review

  • Medullary Thyroid cancer 100%
  • motesanib diphosphate 50%
  • Mutation 44%
  • cabozantinib 42%
  • N-(4-bromo-2-fluorophenyl)-6-methoxy-7-((1-methylpiperidin-4-yl)methoxy)quinazolin-4-amine 41%
  7 Scopus citations

• Synergistic action of a RAF inhibitor and a dual PI3K/mTOR inhibitor in thyroid cancer

  Jin, N., Jiang, T., Rosen, D. M., Nelkin, B. D. & Ball, D. W., Oct 15 2011, In: Clinical Cancer Research. 17, 20, p. 6482-6489 8 p.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • Phosphoinositide-3 Kinase Inhibitors 100%
  • RAF265 89%
  • Phosphatidylinositol 3-Kinase 71%
  • Thyroid Neoplasms 71%
  • Extracellular Signal-Regulated MAP Kinases 61%
  66 Scopus citations
• 2010

  Inhibiting the cyclin-dependent kinase CDK5 blocks pancreatic cancer formation and progression through the suppression of Ras-Ral signaling

  Feldmann, G., Mishra, A., Hong, S. M., Bisht, S., Strock, C. J., Ball, D. W., Goggins, M., Maitra, A. & Nelkin, B. D., Jun 1 2010, In: Cancer Research. 70, 11, p. 4460-4469 10 p.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • Cyclin-Dependent Kinase 5 100%
  • Cyclin-Dependent Kinases 79%
  • Pancreatic Neoplasms 64%
  • Neoplasm Metastasis 13%
  • Phosphotransferases 8%
  117 Scopus citations

• Medullary carcinoma: Clinical practice guidelines in oncology™

  Michael Turtle, R., Ball, D. W., Byrd, D., Daniels, G. H., Dilawari, R. A., Doherty, G. M., Duh, Q. Y., Ehya, H., Farrar, W. B., Haddad, R. I., Kandeel, F., Kloos, R. T., Kopp, P., Lamonica, D. M., Loree, T. R., Lydiatt, W. M., McCaffrey, J., Olson, J. A., Parks, L., Ridge, J. A., & 5 othersShah, J. P., Sherman, S. I., Waguespack, S. G., Wang, T. N. & Wirth, L. J., May 2010, In: JNCCN Journal of the National Comprehensive Cancer Network. 8, 5, p. 512-530 19 p.

  Research output: Contribution to journal › Review article › peer-review

  • Practice Guidelines 66%
  • Medullary Thyroid cancer 35%
  • Anaplastic Thyroid Carcinoma 20%
  • Guidelines 18%
  • Thyroid Nodule 16%
  53 Scopus citations

• Selectively targeting mutant BRAF in thyroid cancer

  Ball, D. W., Jan 2010, In: Journal of Clinical Endocrinology and Metabolism. 95, 1, p. 60-61 2 p.

  Research output: Contribution to journal › Editorial › peer-review

  Open Access
  13 Scopus citations

• Thyroid carcinoma

  Tuttle, R. M., Ball, D. W., Byrd, D., Dilawari, R. A., Doherty, G. M., Duh, Q. Y., Ehya, H., Farrar, W. B., Haddad, R. I., Kandeel, F., Kloos, R. T., Kopp, P., Lamonica, D. M., Loree, T. R., Lydiatt, W. M., McCaffrey, J. C., Olson, J. A., Parks, L., Ridge, J. A., Shah, J. P., & 5 othersSherman, S. I., Sturgeon, C., Waguespack, S. G., Wang, T. N. & Wirth, L. J., Nov 1 2010, In: JNCCN Journal of the National Comprehensive Cancer Network. 8, 11, p. 1228-1274 47 p.

  Research output: Contribution to journal › Review article › peer-review

  Open Access
  170 Scopus citations
• 2009

  Achaete-scute complex homologue 1 regulates tumor-initiating capacity in human small cell lung cancer

  Jiang, T., Collins, B. J., Jin, N., Watkins, D. N., Brock, M. V., Matsui, W., Nelkin, B. D. & Ball, D. W., Feb 1 2009, In: Cancer Research. 69, 3, p. 845-854 10 p.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • Small Cell Lung Carcinoma 100%
  • Neoplasms 29%
  • Heterografts 27%
  • Basic Helix-Loop-Helix Transcription Factors 20%
  • Aldehyde Dehydrogenase 19%
  127 Scopus citations

• American Thyroid Association guidelines for management of medullary thyroid cancer: an adult endocrinology perspective.

  Ball, D. W., Jun 2009, In: Thyroid : official journal of the American Thyroid Association. 19, 6, p. 547-550 4 p.

  Research output: Contribution to journal › Comment/debate › peer-review
  16 Scopus citations

• Dual inhibition of mitogen-activated protein kinase kinase and mammalian target of rapamycin in differentiated and anaplastic thyroid cancer

  Jin, N., Jiang, T., Rosen, D. M., Nelkin, B. D. & Ball, D. W., 2009, In: Journal of Clinical Endocrinology and Metabolism. 94, 10, p. 4107-4112 6 p.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • Anaplastic Thyroid Carcinoma 100%
  • Thyroid 87%
  • TOR Serine-Threonine Kinases 78%
  • Mitogen-Activated Protein Kinase Kinases 76%
  • Thyroid Neoplasms 61%
  65 Scopus citations

• Medullary Thyroid Cancer

  Ball, D. W., Jan 1 2009, Clinical Management of Thyroid Disease. Elsevier, p. 399-405 7 p.

  Research output: Chapter in Book/Report/Conference proceeding › Chapter
  1 Scopus citations

• NCCN Task Force: Clinical utility of PET in a variety of tumor types

  Podoloff, D. A., Ball, D. W., Ben-Josef, E., Benson, A. B., Cohen, S. J., Coleman, R. E., Delbeke, D., Ho, M., Ilson, D. H., Kalemkerian, G. P., Lee, R. J., Loeffler, J. S., Macapinlac, H. A., Morgan, R. J., Siegel, B. A., Singhal, S., Tyler, D. S. & Wong, R. J., Jan 1 2009, In: JNCCN Journal of the National Comprehensive Cancer Network. 7, SUPPL. 2, p. S1-S25

  Research output: Contribution to journal › Review article › peer-review

  • Advisory Committees 100%
  • Neoplasms 30%
  • Small Cell Lung Carcinoma 26%
  • Esophageal Neoplasms 24%
  • Sarcoma 22%
  87 Scopus citations
• 2007

  Medullary thyroid cancer: Therapeutic targets and molecular markers

  Ball, D. W., Jan 1 2007, In: Current opinion in oncology. 19, 1, p. 18-23 6 p.

  Research output: Contribution to journal › Review article › peer-review

  • Medullary Thyroid cancer 100%
  • Phosphotransferases 24%
  • Biomarkers 20%
  • Phase II Clinical Trials 19%
  • Vascular Endothelial Growth Factor Receptor 19%
  69 Scopus citations

• Medullary Thyroid Cancer: Monitoring and Therapy

  Ball, D. W., Sep 2007, In: Endocrinology and metabolism clinics of North America. 36, 3, p. 823-837 15 p.

  Research output: Contribution to journal › Review article › peer-review

  Open Access

  • Medullary Thyroid cancer 100%
  • Vascular Endothelial Growth Factor Receptor 23%
  • Molecular Imaging 23%
  • Residual Neoplasm 21%
  • Thyroid Neoplasms 20%
  48 Scopus citations

• Selective growth inhibition in BRAF mutant thyroid cancer by the mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244

  Ball, D. W., Jin, N., Rosen, D. M., Dackiw, A., Sidransky, D., Xing, M. & Nelkin, B. D., Dec 2007, In: Journal of Clinical Endocrinology and Metabolism. 92, 12, p. 4712-4718 7 p.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • AZD 6244 100%
  • MAP Kinase Kinase 2 95%
  • MAP Kinase Kinase 1 90%
  • Thyroid 75%
  • Growth Inhibition 72%
  84 Scopus citations

• Thyroid carcinoma

  Sherman, S. I., Angelos, P., Ball, D. W., Byrd, D., Clark, O. H., Daniels, G. H., Dilawari, R. A., Ehya, H., Farrar, W. B., Gagel, R. F., Kandeel, F., Kloos, R. T., Kopp, P., Lamonica, D. M., Loree, T. R., Lydiatt, W. M., McCaffrey, J., Olson, J. A., Ridge, J. A., Shah, J. P., & 3 othersSisson, J. C., Tuttle, R. M. & Urist, M. M., Jul 2007, In: JNCCN Journal of the National Comprehensive Cancer Network. 5, 6, p. 568-621 54 p.

  Research output: Contribution to journal › Article › peer-review

  • Thyroid Neoplasms 100%
  • Thyroglobulin 29%
  • Thyrotropin 26%
  • Mortality 24%
  • Incidence 24%
  46 Scopus citations

• Unusual case of metastatic neuroendocrine tumor

  Manahan, M. A., Dackiw, A. P. B., Ball, D. W. & Zeiger, M. A., 2007, In: Endocrine Practice. 13, 1, p. 72-76 5 p.

  Research output: Contribution to journal › Article › peer-review

  • Neuroendocrine Tumors 100%
  • Growth Hormone 84%
  • Pituitary Neoplasms 72%
  • Acromegaly 54%
  • Hyperplasia 39%
  4 Scopus citations
• 2006

  Activity of irinotecan and the tyrosine kinase inhibitor CEP-751 in medullary thyroid cancer

  Strock, C. J., Park, J. I., Rosen, D. M., Ruggeri, B., Denmeade, S. R., Ball, D. W. & Nelkin, B. D., Jan 2006, In: Journal of Clinical Endocrinology and Metabolism. 91, 1, p. 79-84 6 p.

  Research output: Contribution to journal › Article › peer-review

  • CEP 751 100%
  • Irinotecan 68%
  • Tyrosine Kinase Inhibitor 62%
  • Medullary Thyroid cancer 56%
  • Thyroid 55%
  40 Scopus citations

• Clinical aspects of medullary thyroid carcinoma

  Ball, D. W., Dec 1 2006, Thyroid Cancer (Second Edition): A Comprehensive Guide to Clinical Management. Humana Press, p. 581-589 9 p.

  Research output: Chapter in Book/Report/Conference proceeding › Chapter

  • Medullary Thyroid cancer 100%
  • Thyroid Neoplasms 40%
  • Proto-Oncogenes 23%
  • Calcitonin 22%
  • Neoplasms 19%

• Cyclin-dependent kinase 5 activity controls cell motility and metastatic potential of prostate cancer cells

  Strock, C. J., Park, J. I., Nakakura, E. K., Bova, G. S., Isaacs, J. T., Ball, D. W. & Nelkin, B. D., Aug 1 2006, In: Cancer Research. 66, 15, p. 7509-7515 7 p.

  Research output: Contribution to journal › Article › peer-review

  • Cyclin-Dependent Kinase 5 100%
  • Cell Movement 55%
  • Prostatic Neoplasms 53%
  • Neoplasm Metastasis 15%
  • Roscovitine 13%
  119 Scopus citations

• Robot-assisted cortical-sparing adrenalectomy in a patient with Von Hippel-Lindau disease and bilateral pheochromocytomas separated by 9 years

  St. Julien, J., Ball, D. & Schulick, R., Oct 1 2006, In: Journal of Laparoendoscopic and Advanced Surgical Techniques. 16, 5, p. 473-477 5 p.

  Research output: Contribution to journal › Article › peer-review

  • von Hippel-Lindau Disease 100%
  • Adrenalectomy 82%
  • Pheochromocytoma 80%
  • Germ-Line Mutation 27%
  • Adrenal Glands 25%
  30 Scopus citations
• 2005

  GDNF-induced leukemia inhibitory factor can mediate differentiation via the MEK/ERK pathway in pheochromocytoma cells derived from nf1-heterozygous knockout mice

  Park, J. I., Powers, J. F., Tischler, A. S., Strock, C. J., Ball, D. W. & Nelkin, B. D., Feb 1 2005, In: Experimental cell research. 303, 1, p. 79-88 10 p.

  Research output: Contribution to journal › Article › peer-review

  • Leukemia Inhibitory Factor 100%
  • Glial Cell Line-Derived Neurotrophic Factor 98%
  • Pheochromocytoma 83%
  • Mitogen-Activated Protein Kinase Kinases 81%
  • Extracellular Signal-Regulated MAP Kinases 81%
  14 Scopus citations

• Interleukin-1β can mediate growth arrest and differentiation via the leukemia inhibitory factor/JAK/STAT pathway in medullary thyroid carcinoma cells

  Park, J. I., Strock, C. J., Ball, D. W. & Nelkin, B. D., Feb 7 2005, In: Cytokine. 29, 3, p. 125-134 10 p.

  Research output: Contribution to journal › Article › peer-review

  • Leukemia Inhibitory Factor 100%
  • Medullary Thyroid cancer 94%
  • Thyroid 93%
  • Interleukin-1 74%
  • U0126 71%
  27 Scopus citations

• Regulation of neuroendocrine differentiation in gastrointestinal carcinoid tumor cells by notch signaling

  Nakakura, E. K., Sriuranpong, V. R., Kunnimalaiyaan, M., Hsiao, E. C., Schuebel, K. E., Borges, M. W., Jin, N., Collins, B. J., Nelkin, B. D., Chen, H. & Ball, D. W., Jul 2005, In: Journal of Clinical Endocrinology and Metabolism. 90, 7, p. 4350-4356 7 p.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • Carcinoid Tumor 100%
  • Serotonin 97%
  • Developmental 79%
  • Signal Transduction 68%
  • Effector 47%
  81 Scopus citations

• Thyroid carcinoma: Clinical practice guidelines

  Sherman, S. I., Angelos, P., Ball, D. W., Beenken, S. W., Byrd, D., Clark, O. H., Daniels, G. H., Dilawari, R. A., Ehya, H., Farrar, W. B., Gagel, R. F., Kandeel, F., Kloos, R. T., Kopp, P., Lamonica, D. M., Loree, T. R., Lydiatt, W. M., McCaffrey, J., Olson, J. A., Ridge, J. A., & 4 othersRobbins, R., Shah, J. P., Sisson, J. C. & Thompson, N. W., May 2005, In: JNCCN Journal of the National Comprehensive Cancer Network. 3, 3, p. 404-457 54 p.

  Research output: Contribution to journal › Review article › peer-review

  • Thyroid Neoplasms 100%
  • Practice Guidelines 92%
  • Mortality 37%
  • Incidence 24%
  • Early Diagnosis 19%
  64 Scopus citations
• 2004

  Achaete-scute homolog-1 and Notch in lung neuroendocrine development and cancer

  Ball, D. W., Feb 20 2004, In: Cancer Letters. 204, 2, p. 159-169 11 p.

  Research output: Contribution to journal › Article › peer-review

  • Basic Helix-Loop-Helix Transcription Factors 100%
  • Neuroendocrine Cells 92%
  • Adrenal Medulla 92%
  • Neurobiology 84%
  • Neuroendocrine Tumors 82%
  98 Scopus citations

• Clues to target Notch2 in medulloblastoma

  Eberhart, Fan, Mikolaenko, I., Elhassan, I., Ni, X. Z., Wang, Y., Ball, D., Brat, D. & Perry, A., Dec 2004, In: Cancer Biology and Therapy. 3, 12, p. 1192-1199 8 p.

  Research output: Contribution to journal › Comment/debate › peer-review

  Open Access

• Notch1 and Notch2 have opposite effects on embryonal brain tumor growth

  Fan, X., Mikolaenko, I., Elhassan, I., Ni, X. Z., Wang, Y., Ball, D., Brat, D. J., Perry, A. & Eberhart, C. G., Nov 1 2004, In: Cancer Research. 64, 21, p. 7787-7793 7 p.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • Brain Neoplasms 100%
  • Medulloblastoma 65%
  • Growth 54%
  • Gene Amplification 41%
  • Neoplasms 34%
  329 Scopus citations

• Notch inhibits Ptf1 function and acinar cell differentiation in developing mouse and zebrafish pancreas

  Esni, F., Ghosh, B., Biankin, A. V., Lin, J. W., Albert, M. A., Yu, X., MacDonald, R. J., Civin, C. I., Real, F. X., Pack, M. A., Ball, D. W. & Leach, S. D., Sep 2004, In: Development. 131, 17, p. 4213-4224 12 p.

  Research output: Contribution to journal › Article › peer-review

  • Acinar Cells 100%
  • Zebrafish 86%
  • Pancreas 72%
  • Cell Differentiation 68%
  • Embryonic Structures 27%
  170 Scopus citations

• Notch in lung development and lung cancer

  Collins, B. J., Kleeberger, W. & Ball, D. W., Sep 2004, In: Seminars in Cancer Biology. 14, 5, p. 357-364 8 p.

  Research output: Contribution to journal › Article › peer-review

  • Lung Neoplasms 100%
  • Lung 67%
  • Morphogenesis 31%
  • Non-Small Cell Lung Carcinoma 28%
  • Adenocarcinoma 24%
  106 Scopus citations
• 2003

  CEP-701 and CEP-751 inhibit constitutively activated RET tyrosine kinase activity and block medullary thyroid carcinoma cell growth

  Strock, C. J., Park, J. I., Rosen, M., Dionne, C., Ruggeri, B., Jones-Bolin, S., Denmeade, S. R., Ball, D. W. & Nelkin, B. D., Sep 1 2003, In: Cancer Research. 63, 17, p. 5559-5563 5 p.

  Research output: Contribution to journal › Article › peer-review

  • CEP 751 100%
  • lestaurtinib 83%
  • Medullary Thyroid cancer 56%
  • Protein-Tyrosine Kinases 40%
  • Growth 22%
  86 Scopus citations